Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901

Thomas Shea, Jeffrey Johnson, Peter Westervelt, Sherif Farag, John McCarty, Asad Bashey, Luis Isola, Lee Anne Baxter-Lowe, Michael Kelly, Kouros Owzar, Charles Linker

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Cancer and Leukemia Group B conducted a phase II study to evaluate the safety and efficacy of a reduced-intensity conditioning regimen with allogeneic transplantation to treat patients with recurrent low-grade B cell malignancies. Patients over age 18 with a diagnosis of relapsed, chemotherapy-sensitive disease underwent transplantation with a matched sibling donor, and conditioning with cyclophosphamide (1 g/m 2/day × 3) and fludarabine phosphate (25 mg/m 2/day × 5). Graft-versus-host prophylaxis included cyclosporine or tacrolimus plus low-dose methotrexate. Forty-four evaluable patients with a median age of 53 and median of 2 prior regimens were accrued. Sixteen patients had follicular non-Hodgkin lymphoma and 28 had histologies including 7 indolent B cell lymphomas, 4 mantle cell, 15 chronic lymphocytic leukemia (CLL), and 2 prolymphocytic leukemia (PLL) patients. The 6-month treatment-related mortality (TRM) was 2.4% and 3-year TRM was 9%. Three-year event-free and overall survival were 0.75 and 0.81 for the follicular patients, 0.59 and 0.71 for the CLL/PLL patients, and 0.55 and 0.64 for the other histologies. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 29%, and extensive chronic GVHD was 18%. This report demonstrates that allogeneic sibling transplantation with a reduced-intensity conditioning regimen is safe and efficacious for patients with advanced indolent B cell malignancies enrolled on a Cooperative Group study.

Original languageEnglish (US)
Pages (from-to)1395-1403
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Homologous Transplantation
Disease-Free Survival
B-Lymphocytes
Neoplasms
B-Cell Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
fludarabine phosphate
Graft vs Host Disease
Siblings
Histology
Follicular Lymphoma
Mortality
Tacrolimus
B-Cell Lymphoma
Methotrexate
Non-Hodgkin's Lymphoma
Cyclophosphamide
Cyclosporine
Leukemia
Transplantation

Keywords

  • Allo transplantation
  • Chemotherapeutic approches
  • Nonmyeloablative

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies : CALGB 109901. / Shea, Thomas; Johnson, Jeffrey; Westervelt, Peter; Farag, Sherif; McCarty, John; Bashey, Asad; Isola, Luis; Baxter-Lowe, Lee Anne; Kelly, Michael; Owzar, Kouros; Linker, Charles.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 9, 09.2011, p. 1395-1403.

Research output: Contribution to journalArticle

Shea, Thomas ; Johnson, Jeffrey ; Westervelt, Peter ; Farag, Sherif ; McCarty, John ; Bashey, Asad ; Isola, Luis ; Baxter-Lowe, Lee Anne ; Kelly, Michael ; Owzar, Kouros ; Linker, Charles. / Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies : CALGB 109901. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 9. pp. 1395-1403.
@article{00f6037541444154b5e6fdc504d42800,
title = "Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901",
abstract = "Cancer and Leukemia Group B conducted a phase II study to evaluate the safety and efficacy of a reduced-intensity conditioning regimen with allogeneic transplantation to treat patients with recurrent low-grade B cell malignancies. Patients over age 18 with a diagnosis of relapsed, chemotherapy-sensitive disease underwent transplantation with a matched sibling donor, and conditioning with cyclophosphamide (1 g/m 2/day × 3) and fludarabine phosphate (25 mg/m 2/day × 5). Graft-versus-host prophylaxis included cyclosporine or tacrolimus plus low-dose methotrexate. Forty-four evaluable patients with a median age of 53 and median of 2 prior regimens were accrued. Sixteen patients had follicular non-Hodgkin lymphoma and 28 had histologies including 7 indolent B cell lymphomas, 4 mantle cell, 15 chronic lymphocytic leukemia (CLL), and 2 prolymphocytic leukemia (PLL) patients. The 6-month treatment-related mortality (TRM) was 2.4{\%} and 3-year TRM was 9{\%}. Three-year event-free and overall survival were 0.75 and 0.81 for the follicular patients, 0.59 and 0.71 for the CLL/PLL patients, and 0.55 and 0.64 for the other histologies. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 29{\%}, and extensive chronic GVHD was 18{\%}. This report demonstrates that allogeneic sibling transplantation with a reduced-intensity conditioning regimen is safe and efficacious for patients with advanced indolent B cell malignancies enrolled on a Cooperative Group study.",
keywords = "Allo transplantation, Chemotherapeutic approches, Nonmyeloablative",
author = "Thomas Shea and Jeffrey Johnson and Peter Westervelt and Sherif Farag and John McCarty and Asad Bashey and Luis Isola and Baxter-Lowe, {Lee Anne} and Michael Kelly and Kouros Owzar and Charles Linker",
year = "2011",
month = "9",
doi = "10.1016/j.bbmt.2011.01.016",
language = "English (US)",
volume = "17",
pages = "1395--1403",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies

T2 - CALGB 109901

AU - Shea, Thomas

AU - Johnson, Jeffrey

AU - Westervelt, Peter

AU - Farag, Sherif

AU - McCarty, John

AU - Bashey, Asad

AU - Isola, Luis

AU - Baxter-Lowe, Lee Anne

AU - Kelly, Michael

AU - Owzar, Kouros

AU - Linker, Charles

PY - 2011/9

Y1 - 2011/9

N2 - Cancer and Leukemia Group B conducted a phase II study to evaluate the safety and efficacy of a reduced-intensity conditioning regimen with allogeneic transplantation to treat patients with recurrent low-grade B cell malignancies. Patients over age 18 with a diagnosis of relapsed, chemotherapy-sensitive disease underwent transplantation with a matched sibling donor, and conditioning with cyclophosphamide (1 g/m 2/day × 3) and fludarabine phosphate (25 mg/m 2/day × 5). Graft-versus-host prophylaxis included cyclosporine or tacrolimus plus low-dose methotrexate. Forty-four evaluable patients with a median age of 53 and median of 2 prior regimens were accrued. Sixteen patients had follicular non-Hodgkin lymphoma and 28 had histologies including 7 indolent B cell lymphomas, 4 mantle cell, 15 chronic lymphocytic leukemia (CLL), and 2 prolymphocytic leukemia (PLL) patients. The 6-month treatment-related mortality (TRM) was 2.4% and 3-year TRM was 9%. Three-year event-free and overall survival were 0.75 and 0.81 for the follicular patients, 0.59 and 0.71 for the CLL/PLL patients, and 0.55 and 0.64 for the other histologies. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 29%, and extensive chronic GVHD was 18%. This report demonstrates that allogeneic sibling transplantation with a reduced-intensity conditioning regimen is safe and efficacious for patients with advanced indolent B cell malignancies enrolled on a Cooperative Group study.

AB - Cancer and Leukemia Group B conducted a phase II study to evaluate the safety and efficacy of a reduced-intensity conditioning regimen with allogeneic transplantation to treat patients with recurrent low-grade B cell malignancies. Patients over age 18 with a diagnosis of relapsed, chemotherapy-sensitive disease underwent transplantation with a matched sibling donor, and conditioning with cyclophosphamide (1 g/m 2/day × 3) and fludarabine phosphate (25 mg/m 2/day × 5). Graft-versus-host prophylaxis included cyclosporine or tacrolimus plus low-dose methotrexate. Forty-four evaluable patients with a median age of 53 and median of 2 prior regimens were accrued. Sixteen patients had follicular non-Hodgkin lymphoma and 28 had histologies including 7 indolent B cell lymphomas, 4 mantle cell, 15 chronic lymphocytic leukemia (CLL), and 2 prolymphocytic leukemia (PLL) patients. The 6-month treatment-related mortality (TRM) was 2.4% and 3-year TRM was 9%. Three-year event-free and overall survival were 0.75 and 0.81 for the follicular patients, 0.59 and 0.71 for the CLL/PLL patients, and 0.55 and 0.64 for the other histologies. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 29%, and extensive chronic GVHD was 18%. This report demonstrates that allogeneic sibling transplantation with a reduced-intensity conditioning regimen is safe and efficacious for patients with advanced indolent B cell malignancies enrolled on a Cooperative Group study.

KW - Allo transplantation

KW - Chemotherapeutic approches

KW - Nonmyeloablative

UR - http://www.scopus.com/inward/record.url?scp=80051663597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051663597&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.01.016

DO - 10.1016/j.bbmt.2011.01.016

M3 - Article

C2 - 21296675

AN - SCOPUS:80051663597

VL - 17

SP - 1395

EP - 1403

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -